49, Xxxxy Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: 49X006 MIFTS: 45	49, Xxxxy Syndrome Categories: Bone diseases, Endocrine diseases, Fetal diseases, Muscle diseases, Neuronal diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for 49, Xxxxy Syndrome

MalaCards integrated aliases for 49, Xxxxy Syndrome:

Name: 49, Xxxxy Syndrome ¹⁹ ⁷⁵

49,xxxxy Syndrome ⁴² ⁵⁸ ⁷¹

Xxxxy Syndrome ¹⁹ ⁴² ⁷⁵

49,xxxxy ¹⁹ ⁷⁵

49,xxxxy Chromosomal Anomaly ⁴²

Chromosome Xxxxy Syndrome ⁴²

Xxxxy Aneuploidy ⁴²

Xxxx Syndrome ⁷⁵

Characteristics:

Prevelance:

49,xxxxy Syndrome: 1-9/1000000 (Europe) ⁵⁸

Age Of Onset:

49,xxxxy Syndrome: Childhood ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Neuronal diseases Reproductive diseases Endocrine diseases Bone diseases Muscle diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Congenital malformations, deformations and chromosomal abnormalities

Chromosomal abnormalities, not elsewhere classified

Other sex chromosome abnormalities, male phenotype, not elsewhere classified

Klinefelter syndrome, male with more than two X chromosomes

Orphanet: ⁵⁸

Rare neurological diseases

Rare infertility disorders

Rare endocrine diseases

Developmental anomalies during embryogenesis

External Ids:

Sources

Summaries for 49, Xxxxy Syndrome

MedlinePlus Genetics: ⁴² 49,XXXXY syndrome is a chromosomal condition in boys and men that causes intellectual disability, developmental delays, physical differences, and an inability to father biological children (infertility). Its signs and symptoms vary among affected individuals.Boys and men with 49,XXXXY syndrome have mild or moderate intellectual disability with learning difficulties. Speech and language development is particularly affected. Most affected boys and men can understand what other people say more easily than they themselves can speak. People with 49,XXXXY syndrome tend to be shy and friendly, but problems with speech and communication can contribute to behavioral issues, including irritability, difficulty tolerating frustration, defiant behavior, and outbursts or temper tantrums.49,XXXXY syndrome is also associated with weak muscle tone (hypotonia) and problems with coordination that delay the development of motor skills, such as sitting, standing, and walking. Affected infants and young boys are often shorter than their peers, but some catch up in height later in childhood or adolescence.Other physical differences associated with 49,XXXXY syndrome include abnormal fusion of certain bones in the forearm (radioulnar synostosis), an unusually large range of joint movement (hyperextensibility), elbow abnormalities, curved pinky fingers (fifth finger clinodactyly), and flat feet (pes planus). Affected individuals have distinctive facial features that can include widely spaced eyes (ocular hypertelorism), outside corners of the eyes that point upward (upslanting palpebral fissures), skin folds covering the inner corner of the eyes (epicanthal folds), and a flat bridge of the nose. Dental abnormalities are also common in this disorder.49,XXXXY syndrome disrupts male sexual development. The penis is often short and underdeveloped, and the testes may be undescended, which means they are abnormally located inside the pelvis or abdomen. The testes are small and do not produce enough testosterone, which is the hormone that directs male sexual development. The shortage of testosterone often leads to incomplete puberty. Starting in adolescence, affected boys and men may have sparse body hair, and some experience breast enlargement (gynecomastia). Their testes do not produce sperm, so all men with 49,XXXXY syndrome are infertile.

MalaCards based summary: 49, Xxxxy Syndrome, also known as 49,xxxxy syndrome, is related to 48,xyyy and hypogonadotropic hypogonadism. The drugs Heptavalent Pneumococcal Conjugate Vaccine and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include testes, breast and heart, and related phenotypes are intellectual disability and hypotonia

GARD: ¹⁹ 49,XXXXY syndrome is a type of chromosome abnormality characterized by the presence of 3 extra X chromosomes in males. It is sometimes referred to as a variant of Klinefelter syndrome, but differs from Klinefelter syndrome in many ways and is more severe. Signs and symptoms of 49,XXXXY syndrome can vary but may include learning difficulties or intellectual disability; low muscle tone; hypogonadism; infertility; delayed growth; distinctive facial features; and a variety of birth defects that may affect the heart, bones, brain and/or kidneys. It is usually not inherited and caused by a random error in cell division.

Orphanet: ⁵⁸ The 49,XXXXY syndrome represents a chromosomal anomaly of the aneuploidic type characterized by the presence of three extra X chromosomes in males.

Wikipedia ⁷⁵ 49,xxxxy: 49,XXXXY syndrome is an extremely rare aneuploidic sex chromosomal abnormality. It occurs in... more...

Xxxx syndrome: Tetrasomy X, also known as 48,XXXX, is a chromosomal disorder in which a female has four, rather than... more...

Sources

Related Diseases for 49, Xxxxy Syndrome

Diseases related to 49, Xxxxy Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)

#	Related Disease	Score
1	48,xyyy	10.6
2	hypogonadotropic hypogonadism	10.6
3	hypogonadism	10.6
4	pseudovaginal perineoscrotal hypospadias	10.4
5	synostosis	10.4
6	hypotonia	10.4
7	47 xxx syndrome	10.4
8	patent ductus arteriosus 1	10.4
9	premature menopause	10.4
10	radioulnar synostosis	10.4
11	tetrasomy x	10.3
12	hypertelorism	10.3
13	nondisjunction	10.3
14	apraxia	10.3
15	hydronephrosis	10.3
16	penis agenesis	10.3
17	cleft palate, isolated	10.2
18	down syndrome	10.2
19	renal hypodysplasia/aplasia 1	10.2
20	cryptorchidism, unilateral or bilateral	10.2
21	heart septal defect	10.2
22	agnosia	10.2
23	cataract	10.2
24	vesicoureteral reflux	10.2
25	sex-chromosome anomaly	10.2
26	hydrops fetalis, nonimmune	10.1
27	scoliosis	10.1
28	epicanthus	10.1
29	factor viii deficiency	10.1
30	strabismus	10.1
31	thrombophilia due to thrombin defect	10.1
32	ureterocele	10.1
33	hydrocephalus, congenital, 1	10.1
34	taurodontism	10.1
35	cognitive function 1, social	10.1
36	dermatitis, atopic	10.1
37	anxiety	10.1
38	pulmonary hypertension	10.1
39	aphasia	10.1
40	umbilical hernia	10.1
41	urinary tract infection	10.1
42	rickets	10.1
43	microcephaly	10.1
44	gestational diabetes	10.1
45	myopia	10.1
46	clubfoot	10.1
47	hypothyroidism	10.1
48	ventricular septal defect	10.1
49	urinary system disease	10.1
50	atrial heart septal defect	10.1

Graphical network of the top 20 diseases related to 49, Xxxxy Syndrome:

Sources

Symptoms & Phenotypes for 49, Xxxxy Syndrome

Human phenotypes related to 49, Xxxxy Syndrome:

⁵⁸ ³⁰ (show top 50) (show all 68)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	intellectual disability ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001249
2	hypotonia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001252
3	global developmental delay ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001263
4	open bite ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0010807
5	carious teeth ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000670
6	azoospermia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000027
7	hypoplasia of penis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0008736
8	decreased testicular size ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0008734
9	infertility ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000789
10	hypogonadism ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000135
11	language impairment ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002463
12	abnormal dental enamel morphology ³⁰	Hallmark (90%)		HP:0000682
13	seizure ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001250
14	scoliosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002650
15	constipation ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002019
16	hypertelorism ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000316
17	chronic otitis media ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000389
18	recurrent respiratory infections ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002205
19	pes planus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001763
20	strabismus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000486
21	cryptorchidism ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000028
22	autism ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000717
23	attention deficit hyperactivity disorder ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0007018
24	epicanthus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000286
25	myopia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000545
26	asthma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002099
27	upslanted palpebral fissure ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000582
28	clinodactyly of the 5th finger ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0004209
29	delayed eruption of teeth ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000684
30	taurodontia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000679
31	hip dislocation ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002827
32	joint hyperflexibility ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0005692
33	blepharophimosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000581
34	radioulnar synostosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002974
35	down-sloping shoulders ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0200021
36	gynecomastia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000771
37	coxa valga ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002673
38	elbow dislocation ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003042
39	renal dysplasia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000110
40	small scrotum ³⁰	Frequent (33%)		HP:0000046
41	abnormal epiphysis morphology ³⁰	Frequent (33%)		HP:0005930
42	tremor ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001337
43	short neck ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000470
44	depressed nasal bridge ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0005280
45	type ii diabetes mellitus ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0005978
46	mandibular prognathia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000303
47	short stature ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004322
48	gastroesophageal reflux ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002020
49	brachycephaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000248
50	cleft palate ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000175

Sources

Drugs & Therapeutics for 49, Xxxxy Syndrome

Drugs for 49, Xxxxy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4

Immunologic Factors

Phase 4

Cocaine

Approved, Illicit

Phase 3

50-36-2

446220 5760

Aluminium phosphate

Approved, Investigational

Phase 3

7784-30-7

Fluticasone

Approved, Experimental

Phase 2, Phase 3

90566-53-3

4659387 5311101

Hemagglutinins

Phase 3

Agglutinins

Phase 3

Bronchodilator Agents

Phase 2, Phase 3

Anti-Asthmatic Agents

Phase 2, Phase 3

Anti-Allergic Agents

Phase 2, Phase 3

Xhance

Phase 2, Phase 3

Respiratory System Agents

Phase 2, Phase 3

Anti-Inflammatory Agents

Phase 2, Phase 3

Dermatologic Agents

Phase 2, Phase 3

polysaccharide-K

Phase 3

Aluminum hydroxide

Approved, Investigational

Phase 2

21645-51-2

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Fluorouracil

Approved

Phase 2

51-21-8

3385

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Molgramostim

Investigational

Phase 2

99283-10-0

N-(2-aminoethyl)-5-isoquinolinesulfonamide

Phase 1, Phase 2

Angiogenesis Inhibitors

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Vitamin B Complex

Phase 2

Folic Acid Antagonists

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Metformin

Approved

Phase 1

1115-70-4, 657-24-9

4091

Aluminum sulfate

Approved

Phase 1

10043-01-3

Immunoglobulins

Phase 1

Antibodies

Phase 1

Ethanol

Approved

64-17-5

702

Bortezomib

Approved, Investigational

179324-69-7

387447 93860

Iron

Approved

7439-89-6

29936

Iodine

Approved, Investigational

7553-56-2

807

Mecobalamin

Approved, Investigational

13422-55-4

Hydroxocobalamin

Approved

13422-51-0

15589840 44475014

Testosterone

Approved, Investigational

58-22-0

5408 6013

Cyanocobalamin

Approved, Nutraceutical

68-19-9

24892734 16212801 44176380

Cadexomer iodine

Experimental

94820-09-4

Interventional clinical trials:

(show top 50) (show all 88)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (IIV) in Adults 18-49 Years of Age	Completed	NCT03101462	Phase 4
2	An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age	Completed	NCT00192140	Phase 4
3	A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 TO 49 YEARS OF AGE IN INDIA	Active, not recruiting	NCT05329259	Phase 4
4	A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age	Unknown status	NCT00216242	Phase 3
5	Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok® Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age	Completed	NCT02290509	Phase 3
6	A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE	Completed	NCT03828617	Phase 3
7	A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.	Completed	NCT05045144	Phase 3
8	A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age	Completed	NCT00860067	Phase 2, Phase 3
9	A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent Virus-Like Particle Influenza Vaccine in Healthy Adults 18-49 Years of Age	Completed	NCT03321968	Phase 3
10	Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 Years	Completed	NCT00539981	Phase 3
11	A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age	Completed	NCT00952705	Phase 3
12	A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)	Completed	NCT03547167	Phase 3
13	A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years	Completed	NCT00192335	Phase 3
14	A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Consistency of Three Consecutive Lots of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs in Healthy Subjects Aged 18 to 49 Years	Completed	NCT00617851	Phase 3
15	Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years.	Completed	NCT00328107	Phase 2, Phase 3
16	A Phase II/III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 18-49 Years	Completed	NCT03390166	Phase 2, Phase 3
17	A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population	Completed	NCT01734239	Phase 3
18	A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old	Recruiting	NCT05054322	Phase 2, Phase 3	Fluticasone Propionate
19	Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years.	Recruiting	NCT05513053	Phase 3
20	A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age	Active, not recruiting	NCT04605159	Phase 3	Placebo
21	A Phase III, Randomized, Open-label, Active Vaccine-controlled Crossover Study to Evaluate the Reactogenicity, Safety and Immune Response of Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Girls From 9 to 17 Years of Age, and in Non-pregnant Adult Women From 18 to 49 Years of Age	Active, not recruiting	NCT05169905	Phase 3
22	A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age	Active, not recruiting	NCT05464420	Phase 3
23	A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers	Active, not recruiting	NCT04980391	Phase 3	Placebo
24	A Randomized, Observer-Blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-49 Years of Age	Not yet recruiting	NCT05040789	Phase 3
25	A Phase IIIB, Open Label, Non-randomized, Controlled, Multi-country Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Repeat Vaccination With 120 µg Dose of RSV Maternal Vaccine During Subsequent Pregnancy in Healthy Maternal Participants 18-49 Years of Age	Withdrawn	NCT05229068	Phase 3
26	A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE	Completed	NCT04071158	Phase 2
27	Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years	Completed	NCT02669121	Phase 2
28	Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years	Completed	NCT00845429	Phase 2
29	A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults	Completed	NCT02307851	Phase 2
30	A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85	Completed	NCT04473690	Phase 1, Phase 2
31	A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS	Completed	NCT04032093	Phase 2
32	A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49	Completed	NCT01147068	Phase 1, Phase 2
33	A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE	Completed	NCT03170609	Phase 2
34	Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years	Completed	NCT01612000	Phase 1, Phase 2
35	Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age	Completed	NCT00623181	Phase 2
36	A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 Years to 49 Years	Completed	NCT02894840	Phase 1, Phase 2
37	A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older.	Completed	NCT01224262	Phase 1, Phase 2
38	A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years	Completed	NCT01320696	Phase 1, Phase 2
39	OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.	Completed	NCT01802684	Phase 2
40	A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49%	Recruiting	NCT04856176	Phase 2	Granulocyte-Macrophage Colony-Stimulating Factor;Pembrolizumab;pemetrexed;Paclitaxel;Carboplatin
41	A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE	Active, not recruiting	NCT04766086	Phase 2
42	A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain	Not yet recruiting	NCT05560646	Phase 2	OG-6219;Placebo
43	Phase I Randomized Double Blind Placebo-controlled Study of Universal Influenza Vector Vaccine "UniFluVec" of Two Dose Levels After Two Intranasal Administrations in Healthy Volunteers at the Age From 18 to 49 Years Old	Completed	NCT04650971	Phase 1
44	A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet β-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin	Completed	NCT01933256	Phase 1	HIP2B;Placebo
45	A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age	Completed	NCT00641017	Phase 1
46	A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study	Completed	NCT00730457	Phase 1
47	A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years	Completed	NCT03343626	Phase 1	Placebo
48	A Phase 1, Randomized, Controlled, Observer-blinded Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults Aged 18 To 49 Years	Completed	NCT02955160	Phase 1
49	Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.	Completed	NCT00599443	Phase 1
50	A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.	Completed	NCT03594890	Phase 1

Search NIH Clinical Center for 49, Xxxxy Syndrome

Sources

Genetic Tests for 49, Xxxxy Syndrome

Sources

Anatomical Context for 49, Xxxxy Syndrome

Organs/tissues related to 49, Xxxxy Syndrome:

MalaCards : Testes, Breast, Heart, Brain, Skin, Lung, Lymph Node

Sources

Publications for 49, Xxxxy Syndrome

Articles related to 49, Xxxxy Syndrome:

(show top 50) (show all 30000)

#	Title	Authors	PMID	Year
1	Application of Component Separation and Short-Term Outcomes in Ventral Hernia Repairs. ⁶²	Solano QP...Telem D	36244222	2023
2	Quantitative phosphoproteomic analysis of mice with liver fibrosis by DIA mass spectrometry analysis with PRM verification. ⁶²	Zhang L...Jiang H	36336261	2023
3	Risk Factors in a Pediatric Population for Postoperative Intracranial Infection Following Endoscopic Endonasal Skull Base Surgery and the Role of Antibiotic Prophylaxis. ⁶²	Palmieri D...Snyderman CH	36050937	2023
4	Corrigendum to "The RNA binding protein HuR influences skeletal muscle metabolic flexibility in rodents and humans" [Metab. 97 (2019) 40-49]. ⁶²	Mynatt RL...Warfel JD	36410080	2023
5	Yogurt Technique for Descemet Membrane Endothelial Keratoplasty Graft Preparation: Early Clinical Outcomes. ⁶²	Moramarco A...Fontana L	35942529	2023
6	The Rising Incidence of Early-Onset Colorectal Cancer in Germany. ⁶²	Tanaka LF...Buttmann-Schweiger N	36471648	2023
7	Intranasal interferon-beta alleviates anxiety and depressive-like behaviors by modulating microglia polarization in an Alzheimer's disease model. ⁶²	Farhangian M...Dargahi L	36396023	2023
8	Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. ⁶²	Verma S...Kosiborod MN	36467859	2023
9	Improved visualization of the wrist at lower radiation dose with photon-counting-detector CT. ⁶²	Rajendran K...Fletcher J	35831718	2023
10	Disrupting the Link between Corporal Punishment Exposure and Adolescent Aggression: The Role of Teacher-Child Relationships. ⁶²	Neaverson A...Eisner M	36100731	2022
11	Short-Term Acoustic Effects of Speech Therapy in Transgender Women: A Randomized Controlled Trial. ⁶²	Leyns C...D'haeseleer E	36455242	2022
12	Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. ⁶²	Anker SD...Zannad F	36471037	2022
13	Breast cancer recurrence: factors impacting occurrence and survival. ⁶²	Courtney D...Kerin MJ	35076871	2022
14	Identifying women with fear of childbirth with the Dutch Fear of Birth Scale and its added value for consultations. ⁶²	den Boer I...van Pampus MG	34907846	2022
15	Development and validation of the Professional Nursing Support Scale for Chinese patients with cancer. ⁶²	Song Y...Wang W	34658105	2022
16	Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats. ⁶²	Castro AL...Treesukosol Y	36426786	2022
17	The what's, where's and why's of miscarriage: evidence from the 2017 Ghana Maternal Health Survey. ⁶²	Sumankuuro J...Derbile EK	36334582	2022
18	Pretreatment attrition and treatment initiation delay among rifampicin-resistant tuberculosis patients in Lagos, Nigeria: a retrospective cohort study. ⁶²	Adejumo OA...Olusola-Faleye B	35710310	2022
19	Design, synthesis, and biological evaluation of low-toxic lappaconitine derivatives as potential analgesics. ⁶²	Li Y...Zhou XL	36162215	2022
20	Electronically Monitored Adherence to Short-Term Antibiotic Therapy in Children. ⁶²	Youngster I...Goldman M	36317476	2022
21	Evaluation of recurrent dislocation of the patella in children with MRI: Goldthwait technique combined with lateral release, and VMO advancement-a retrospective study of 85 knees. ⁶²	Megremis P...Megremis O	34027575	2022
22	Pulse pressure and all-cause mortality in ischaemic heart failure patients: a prospective cohort study. ⁶²	Qiu W...Li L	36223284	2022
23	Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma. ⁶²	Sachpekidis C...Dimitrakopoulou-Strauss A	36474125	2022
24	Learning curve and functional outcomes after laser enucleation of the prostate for benign prostate hyperplasia according to surgeon's caseload. ⁶²	Kosiba M...Becker A	36289106	2022
25	Ambulatory Cardiac Monitoring in Infants with Supraventricular Tachycardia. ⁶²	Hidalgo Corral NM...Clark BC	35570217	2022
26	Age-specific random day serum antimüllerian hormone reference values for women of reproductive age in the general population: a large Chinese nationwide population-based survey. ⁶²	Hao Y...Qiao J	35934115	2022
27	Variability and efficacy in treatment effects on manic symptoms with lithium, anticonvulsants, and antipsychotics in acute bipolar mania: A systematic review and meta-analysis. ⁶²	Hsu TW...Carvalho AF	36247926	2022
28	Persistence of an epidemic cluster of Rhodotorula mucilaginosa in multiple geographic regions in China and the emergence of a 5-flucytosine resistant clone. ⁶²	Huang JJ...Xu YC	35343400	2022
29	The Journal of Rheumatology, Volume 49, 2022. ⁶²		36455935	2022
30	Betulinic acid counteracts the lipid accumulation in Caenorhabditis elegans by modulation of nhr-49 expression. ⁶²	Savova MS...Georgiev MI	36242845	2022
31	A new multi-analyte LC-MS/MS screening method for detection of 120 NPS and 49 drugs in hair. ⁶²	Rubicondo J...Vaiano F	36453750	2022
32	In Regards to Barufaldi et al. Med Phys 49(4), 2220-2232. ⁶²	Glick SJ	36468268	2022
33	Breast cancer diagnosis in Inner-City African American and Hispanic women: The importance of early screening. ⁶²	Zhang Z...Ojutiku O	36194959	2022
34	Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients. ⁶²	Nguyen Y...AP-HP-Centre Monoclonal Antibodies Working Group	35926762	2022
35	Physically fit with a higher cancer risk? Influences of cervical cancer screening among a sample of physically active women ages 21-49 living in the United States. ⁶²	Ewing AP...Best AL	36157713	2022
36	Assessment of prognostic factors in pediatric adrenocortical tumors: a systematic review and evaluation of a modified S-GRAS score. ⁶²	Riedmeier M...Wiegering V	36193775	2022
37	[Clinical analysis of 49 cases of non-inflammasome related conditions]. ⁶²	Zhang CH...Song HM	36444428	2022
38	Clinical and prognostic role of 2-[18F]FDG PET/CT and sarcopenia in treatment-naïve patients with T-cell lymphoblastic lymphoma. ⁶²	Tan X...Jiang L	36123452	2022
39	Risk factors for depressive symptoms by age group among human immunodeficiency virus-infected adults in Korea. ⁶²	Kang CR...Yang SJ	34612099	2022
40	The effect of dietary intake on apneic performance, cardiovascular and splenic responses during repeated breath holds. ⁶²	Elia A...Gennser M	36222874	2022
41	Long-term metabolic fate and mortality in obesity without metabolic syndrome. ⁶²	Karajamaki AJ...Ukkola O	35594302	2022
42	Dysplastic crypts in asymmetric branching found in ulcerative colitis-associated dysplasia. ⁶²	Rubio CA...Lang-Schwarz C	36308948	2022
43	Does childhood chemotherapy affect mandibular bone structures in a lifetime? ⁶²	Kis HC...Aksu S	36459049	2022
44	Assessing Knowledge and Perceptions About Cancer Among American Indians of the Zuni Pueblo, NM. ⁶²	Safi S...Shah V	33963443	2022
45	Determinants of cervical cancer screening service utilization among women attending healthcare services in Amhara region referral hospitals: a case-control study. ⁶²	Legasu TD...Ali MA	36461054	2022
46	Hemoglobin A1C can differentiate subjects with GCK mutations among patients suspected to have MODY. ⁶²	Yilmaz Uzman C...Demir K	36197956	2022
47	Practices and attitudes towards tuberculosis and latent tuberculosis infection screening in people living with HIV/AIDS among HIV physicians in Japan. ⁶²	Kawatsu L...Uchimura K	36463211	2022
48	Effect of Intraoperative Esketamine Infusion on Postoperative Sleep Disturbance After Gynecological Laparoscopy: A Randomized Clinical Trial. ⁶²	Qiu D...Yang JJ	36454569	2022
49	Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders. ⁶²	Yuasa A...Ikeda S	36205907	2022
50	[The impact of using intraoperative photodynamic diagnosis on the prognosis of bladder cancer]. ⁶²	Albarghouth MH...Hamza A	31559609	2022